Arcus Biosciences, Inc. (RCUS)
Develops cancer drugs targeting immune pathways and tumor cell survival mechanisms.
$27.01-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+194.9%
The outlook
RCUS trades at $27.01, sitting well above both its 50- and 200-day moving averages with strong upward momentum. Analyst consensus is "Strong Buy," and the average price target sits roughly 36% above the current price. The stock sits near the upper end of its 52-week range, reflecting sustained strength over the past year.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 12 analysts
Price trendAbove its 50- & 200-day averages
52-week range79% of the way from its 52-week low to high
Price targetAvg target +36% vs current price
Analyst price target
~12-month · 12 analysts$36.83average target+36.4% vs now
Now $27.01
Low $22.00High $47.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.40B
52-wk high
$31.74
52-wk low
$8.84
50-day avg
$26.52
200-day avg
$23.04
Trailing P/E
—